Drug intelligence / Profile preview

QinSong

Development stage: Unknown
Lead developer: Suzhou Siyuan Natural Products Research and Development
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

QinSong is a botanical-based oral solution developed by Suzhou Siyuan Natural Products Research and Development for the treatment of acute pharyngitis. Derived from natural products, the drug is designed to alleviate symptoms of throat inflammation and infection. It has been evaluated in Phase 1 clinical trials in China (e.g., CTR20170846) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. As a natural product-derived therapeutic, its mechanism of action likely involves multi-target anti-inflammatory and soothing effects on the pharyngeal mucosa.

Brand names: QinSong
Other names: QinSong oral solution

Beyond the preview

Go deeper on QinSong.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QinSong.

Explore the full profile